ZYNE - Zynerba Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.91
-2.51 (-24.09%)
At close: 4:00PM EDT

7.95 +0.04 (0.51%)
After hours: 5:59PM EDT

Stock chart is not supported by your current browser
Previous Close10.42
Open7.95
Bid7.95 x 900
Ask8.00 x 400
Day's Range7.43 - 8.13
52 Week Range5.42 - 19.15
Volume4,000,881
Avg. Volume267,168
Market Cap107.271M
Beta4.88
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire14 hours ago

    Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    Zynerba Pharmaceuticals, Inc. (ZYNE) today announced the pricing of an underwritten public offering of 4,062,500 shares of its common stock at a price of $8.00 per share, for a gross deal size of $32.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Zynerba has granted the underwriters a 30-day option to purchase up to 609,375 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Cantor Fitzgerald & Co. is acting as the sole book-running manager.

  • GlobeNewswireyesterday

    Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Zynerba Pharmaceuticals, Inc. (ZYNE) today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.  All of the shares to be sold in the offering will be offered by Zynerba.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Zynerba intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. Cantor Fitzgerald & Co. is acting as the sole book-running manager.

  • GlobeNewswire9 days ago

    Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome

    -Significant Improvements in Behavioral Symptoms Observed in Patients and Sustained through 38 Weeks of Treatment with ZYN002-- Presentation Today at the 16 th NFXF International Fragile X Conference-. ...

  • GlobeNewswire12 days ago

    Zynerba Pharmaceuticals Initiates CONNECT-FX, a Pivotal Clinical Trial of ZYN002 in Fragile X Syndrome

    DEVON, Pa., July 09, 2018 (GLOBE NEWSWIRE) --  Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the initiation of a multi-national, randomized, double blind placebo controlled Clinical study of Cannabidiol (CBD) in Children and Adolescents with Fragile X (CONNECT-FX). The CONNECT-FX trial will evaluate the efficacy and safety of ZYN002 (CBD Gel) in children ages three to 17 with full mutation Fragile X syndrome (FXS). FXS is a genetic condition that causes intellectual disability, behavioral and learning challenges and is the most common known single gene cause of autism spectrum disorder.

  • GlobeNewswire16 days ago

    Zynerba Pharmaceuticals Announces Top Line Results from ZYN001 THC-Prodrug Patch Phase 1 Study

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced top line results from a Phase 1 clinical program studying ZYN001, the Company’s patent-protected, pro-drug of tetrahydrocannabinol (THC) delivered via a transdermal patch, in healthy volunteers. As a result of these data, the Company will focus its development efforts and investments on the ZYN002 Fragile X syndrome, developmental and epileptic encephalopathy (DEE) and adult refractory epilepsy programs. The Company expects that this change will extend its cash runway into the second half of 2019.

  • GlobeNewswire2 months ago

    Zynerba Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

    Zynerba Pharmaceuticals, Inc. (ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the Jefferies 2018 Global Healthcare Conference on Thursday June 7, 2018 at 10:30 AM EDT at the Grand Hyatt hotel in New York, NY. Zynerba Pharmaceuticals (ZYNE) is a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders with high unmet medical needs.

  • GlobeNewswire2 months ago

    Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights

    DEVON, Pa., May 08, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...

  • GlobeNewswire3 months ago

    Zynerba Pharmaceuticals Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at the 2018 Annual Meeting of the American Academy of Neurology (AAN)

    Continued Improvement in Seizure Control Seen in Adult Refractory Focal Seizure Patients Receiving ZYN002 through 12 Months of Open Label Exposure. LOS ANGELES, April 25, 2018-- Zynerba Pharmaceuticals, ...

  • GlobeNewswire3 months ago

    Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018

    Zynerba Pharmaceuticals, Inc. (ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced an oral presentation to be given at the16th NFXF (National Fragile X Foundation) International Fragile X Conference. The oral presentation will describe data from the FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) study that highlight the short- and long-term positive impact of ZYN002 on children and adolescents with Fragile X syndrome (FXS). Zynerba is committed to supporting the needs of patients, their families and health care practitioners, and to developing this novel therapy to treat the behavioral symptoms associated with Fragile X syndrome as expeditiously as possible,” said Dr. Liza Squires, Zynerba’s Chief Medical Officer.

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Trending Tickers: Kura Oncology and Zynerba Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / March 13, 2018 / U.S. markets were mixed Mondays as concerns over a potential trade war overshadowed Friday’s jobs data. The Dow Jones Industrial Average declined 0.62 percent ...

  • ACCESSWIRE4 months ago

    Wired News – Zynerba Pharma Held Positive Discussion Meeting with FDA for its ZYN002 Development Strategy

    Stock Monitor: Horizon Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 07, 2018 / Active-Investors.com has just released a free research report on Zynerba Pharma, Inc. (NASDAQ: ZYNE ). If ...

  • ACCESSWIRE7 months ago

    Today’s Research Reports on Trending Tickers: Achillion Pharmaceuticals and Zynerba Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / December 5, 2017 / U.S. markets saw mixed Monday as the Dow reached a new record after investors celebrated the passing of a bill to overhaul the country's tax system while ...

  • ACCESSWIRE10 months ago

    Today's Research Reports on Stocks to Watch: Zynerba Pharmaceuticals and Loxo Oncology

    NEW YORK, NY / ACCESSWIRE / September 29, 2017 / Zynerba scored a big win yesterday after announcing positive results from its trial of ZYN002, a cannabidiol gel that is aimed to reduce symptoms of fragile ...